Related Experiment Videos
Prophylactic treatment in Sweden--overtreatment or optimal model?
1Department of Paediatrics, University of Lund, University Hospital, Malmö, Sweden. Rolf.Ljung@pediatrik.mas.lu.se
Insights
Prophylactic treatment for hemophilia begins early in Sweden, optimizing factor levels to prevent bleeds. Continuous infusion of recombinant concentrates could represent an ideal future treatment model.
Area of Science:
- Pediatric Hematology
- Pharmacokinetics
- Bleeding Disorders
Background:
- Hemophilia management requires effective prophylactic strategies to prevent joint damage.
- Early intervention before joint bleeds is crucial for long-term outcomes in children with hemophilia.
Purpose of the Study:
- To describe the Swedish model of early prophylactic treatment for hemophilia.
- To explore the potential of continuous infusion for an optimal prophylactic regimen.
Main Methods:
- Individualized dosing based on pharmacokinetic studies of Factor VIII (FVIII) or Factor IX (FIX) metabolism.
- Establishing a target FVIII/FIX level of >1% of normal to control bleeding.
Main Results:
- The Swedish model, initiated at 1-1.5 years, demonstrates satisfactory control of bleeding diathesis.
- Pharmacokinetic optimization ensures individualized and effective prophylactic treatment.
Conclusions:
- The Swedish prophylactic model offers a satisfactory outcome for hemophilia management.
- Continuous infusion of recombinant concentrates may represent a future optimal treatment if technically and socially feasible.
Abstract:
At the haemophilia centre in Malmö, Sweden, regular prophylactic treatment is begun at 1-1 1/2 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment.